AMGN

In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.

Yahoo · 1d ago

Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.

Yahoo · 1d ago

Explore this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay dates.

SeekingAlpha · 1d ago

Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.

ChartMill · 1d ago

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Yahoo · 2d ago

Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]

Yahoo · 2d ago

Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $400 to $435.

Benzinga · 2d ago